Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Axsome Therapeutics, Inc. (AXSM)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
26.46+2.33 (+9.66%)
At close: 04:00PM EDT
26.70 +0.24 (+0.91%)
After hours: 07:53PM EDT
Advertisement

Axsome Therapeutics, Inc.

22 Cortlandt Street
16th Floor
New York, NY 10007
United States
212 332 3241
https://www.axsome.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees116

Key Executives

NameTitlePayExercisedYear Born
Dr. Herriot Tabuteau M.D.Founder, Chairman, CEO & Pres1.06MN/A1968
Mr. Nick Pizzie CPA, M.B.A.Chief Financial Officer553.97kN/A1975
Mr. Mark L. JacobsonCOO & Sec.554.72kN/A1983
Mr. Hunter Murdock Esq.Exec. VP of Legal & ComplianceN/AN/AN/A
Dr. Amanda Jones Pharm.D.Sr. VP of Clinical Devel.N/AN/A1983
Ms. Lori Englebert M.B.A.Exec. VP of Commercial & Bus. Devel.N/AN/A1978
Mr. Kevin Laliberte Pharm.D.Exec. VP of Product StrategyN/AN/A1978
Joseph Debrah-Afful CPA, M.B.A.Director of Fin.N/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Corporate Governance

Axsome Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 9. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement